Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients

Publication date: Available online 20 October 2016
Source:Journal of Oral Biology and Craniofacial Research
Author(s): Sachin Rai, Shikha Yadav, Dinesh Kumar, Vijay Kumar, Vidya Rattan
Mucormycosis is an opportunistic, uncommon and serious systemic fungal infection mostly presenting in immunocompromised patients. The combination of surgical debridement, parenteral therapy with Amphotericin B and management of the underlying systemic disease is the standard treatment modality for mucormycosis. The drawback of this regime is the need for long hospitalization due to the serious side effects of Amphotericin B requiring regular monitoring. Oral Posaconazole is one of the newer antifungals that have shown promising results. This paper highlights a case series of rhinomaxillary mucormycosis in immunocompetent patients diagnosed and managed successfully with surgical debridement and oral Posaconazole administration on out-patient basis.



http://ift.tt/2dLyKmY


http://ift.tt/2eGHytl